Long-Term Monitoring and Future Planning
At a Glance
Long-term MPAN care combines regular checks of movement, daily function, swallowing, vision, heart rate, bone health, and breathing-related risks with rehabilitation, palliative care, emotional support, and future planning. Monitoring schedules are individualized.
Living with MPAN is a marathon that requires ongoing attention to shifting needs. While the condition is progressive, it typically moves slowly, often spanning decades. Understanding the long-term patterns seen in research can help you and your care team plan for the future, while remembering that these numbers represent averages and not a fixed destiny for any one person [1].
Tracking Disease Progression
Researchers use specific tools to measure how MPAN changes over time. Being familiar with these can help you understand your doctor’s assessments:
- Mobility Milestones: In a large study of 85 patients, roughly half (50%) of individuals began using a wheelchair full-time after 16 years of living with the disease [1]. Another study found that about 23% of patients were still able to walk after 18 years [2].
- The UPDRS Scale: Doctors use the Unified Parkinson’s Disease Rating Scale (UPDRS) to track movement function over time. In MPAN cohorts, this score typically increases by about 4.5 points per year, reflecting a gradual change in motor skills. However, these tools are used for tracking, and were not designed as individual prognostic tools, so a score change does not mean a fixed disease trajectory [1].
- Daily Activities: The Schwab and England ADL scale measures independence in daily life (like eating and dressing). On average, this score declines by about 3.9% each year [1].
It is important to note that while movement and daily tasks change, some measures, like the Barry-Albright Dystonia Scale (used to track involuntary muscle contractions), may remain relatively stable for long periods in some patients [1].
Examples of Surveillance and Monitoring
Regular monitoring is the key to preventing complications and maintaining comfort. While your doctor will set a schedule based on your specific needs, these are examples of topics you might discuss with your doctor, but there is no single schedule for everyone:
Neurological and Physical Review
- Movement Checks: Regular evaluation of stiffness, tremors, and balance to adjust medications or physical therapy plans [1].
- Autonomic Monitoring: Some patients experience a fast heart rate (tachycardia) or other issues with the “automatic” nervous system. Depending on symptoms, your doctor may check your heart rate or order an EKG to monitor this [3].
- Bone Health: Because reduced mobility can weaken bones, monitoring for bone mineral density is sometimes considered by specialists, especially in children, to prevent fractures [4].
Vision and Communication
- Ophthalmology: Regular exams including Optical Coherence Tomography (OCT) to monitor the health of the optic nerve [5].
- Swallowing Assessments: Clinical reviews for dysphagia (swallowing trouble) are critical to prevent aspiration pneumonia [6]. Aspiration means food or liquid entering the lungs. ‘Silent aspiration’ happens when this occurs without an obvious cough. If you notice coughing or a “wet” voice during meals, a formal swallow study should be done promptly.
Quality of Life and Supportive Care
Long-term care for MPAN is not just about medical tests; it is about supporting the whole person and the family.
- Palliative Care: Often misunderstood as only for the end of life, palliative care is specialized medical care for people living with a serious illness. It focuses on providing relief from symptoms and the stress of the disease [7]. Bringing a palliative team on board early can help with pain management, sleep issues, and complex decision-making.
- Psychological Support: Living with a progressive rare disease can take a significant toll on mental health. Quality of life scores (PedsQL) typically show a gradual decline over time for both pediatric patients and parents [1]. Regular access to counseling or support groups is essential to navigate the emotional journey and prevent caregiver burnout.
- Rehabilitation: Ongoing physical and occupational therapy are not just for early in the diagnosis; they are vital throughout the disease course to adapt to new challenges and maintain the highest possible level of independence [8][9].
Survival in MPAN can vary widely depending on the individual and the onset age. One small retrospective cohort of 23 patients estimated a survival probability of roughly 68% at 14 years, though many individuals live much longer and this statistic does not predict any one person’s life expectancy [2]. The most common life-threatening complications are related to swallowing and respiratory issues, which is why diligent monitoring in these areas is so important.
Common questions in this guide
How do doctors track MPAN progression over time?
How often should MPAN monitoring and testing be done?
How can silent aspiration be detected in MPAN?
Should people with MPAN have heart monitoring?
What supportive care can help someone living with MPAN?
What is the long-term outlook for people with MPAN?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How can we use scales like the UPDRS or the Schwab and England ADL scale to track my/my child's progression specifically?
- 2.Given the risk of heart-rate changes (tachycardia) seen in some studies, should we discuss symptom-triggered EKG or Holter monitoring?
- 3.What is the best way to monitor for 'silent aspiration' as the disease progresses, and when should we repeat a formal swallow study?
- 4.Are there local palliative care specialists who have experience with rare, progressive neurological conditions like NBIA?
- 5.How often should we re-evaluate for assistive technology, such as communication devices or mobility aids, before they are urgently needed?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (9)
- 1
Phenotype and natural history of mitochondrial membrane protein-associated neurodegeneration.
Iankova V, Sparber P, Rohani M, et al.
Brain : a journal of neurology 2024; (147(4)):1389-1398 doi:10.1093/brain/awad357.
PMID: 37831662 - 2
Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders.
Amini E, Rohani M, Lang AE, et al.
Movement disorders clinical practice 2024; (11(1)):53-62 doi:10.1002/mdc3.13933.
PMID: 38291840 - 3
Is there heart disease in cases of neurodegeneration associated with mutations in C19orf12?
Skowronska M, Buksinska-Lisik M, Kmiec T, et al.
Parkinsonism & related disorders 2020; (80()):15-18 doi:10.1016/j.parkreldis.2020.09.014.
PMID: 32932022 - 4
Palliative care in 9 children with neurodegeneration with brain iron accumulation.
Dangel T, Kmieć T, Januszaniec A, Ważny B
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(3)):653-660 doi:10.1007/s10072-019-04099-5.
PMID: 31758347 - 5
Retinal and optic nerve abnormalities in neurodegeneration associated with mutations in C19orf12 (MPAN).
Langwinska-Wosko E, Skowronska M, Kmiec T, Czlonkowska A
Journal of the neurological sciences 2016; (370()):237-240 doi:10.1016/j.jns.2016.09.046.
PMID: 27772766 - 6
Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.
Patino J, Clearman AH, Miller L, Koenig MK
Clinical case reports 2024; (12(7)):e9116 doi:10.1002/ccr3.9116.
PMID: 38919884 - 7
Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration.
Wilson JL, Gregory A, Kurian MA, et al.
Developmental medicine and child neurology 2021; (63(12)):1402-1409 doi:10.1111/dmcn.14980.
PMID: 34347296 - 8
Rehabilitation for Mitochondrial Membrane Protein-Related Neurodegeneration: A Case Study.
Özçelep ÖF, Turhan A, Fi Dan S, Kandemir S
Cureus 2023; (15(12)):e50540 doi:10.7759/cureus.50540.
PMID: 38222195 - 9
Functional impairments in NBIA patients: Preliminary results.
Syczewska M, Stęplowska A, Szczerbik E, et al.
Intractable & rare diseases research 2024; (13(3)):172-177 doi:10.5582/irdr.2024.01019.
PMID: 39220277
This page is for informational purposes only and does not constitute medical advice. Your neurology team should tailor MPAN monitoring, testing, rehabilitation, and future planning to your symptoms, age, and goals.
Get notified when new evidence is published on Mitochondrial membrane protein-associated neurodegeneration.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.